Results 41 to 50 of about 86,601 (293)
Haematologica, 2018 Inflammation and B-cell hyperactivation have been associated with non-Hodgkin lymphoma development. This prospective analysis aimed to further elucidate pre-diagnosis plasma immune marker profiles associated with non-Hodgkin lymphoma risk.
Mara M. Epstein +11 more
doaj +1 more source
Advanced Science, EarlyView.This study finds that CD8⁺ TSCM cells exhibit superior self‐renewal, differentiation, and antiviral activity. Transcriptome and epigenome analyses highlight MAPK cascade regulation in TSCM cells. In vivo, virus‐specific TSCM cells show enhanced persistence and tumor protection.
Xun‐Hong Cao +13 more
wiley +1 more source
T-Cell/Histiocyte Rich Large B-Cell Lymphoma –A Case Series with Review of Literature [PDF]
National Journal of Laboratory Medicine, 2017 T-Cell/Histiocyte Rich Large B-Cell Lymphoma (THRLBCL) is a rare variant of Diffuse Large B Cell Lymphoma (DLBCL). This entity differs from the classical DLBCL in the morphology as well as immunohistochemical expression of various CD markers.
Priavadhana Rajan Prasaad +1 more
doaj +1 more source
Advanced Science, EarlyView.An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang +10 more
wiley +1 more source
Advanced Science, EarlyView.Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong +6 more
wiley +1 more source
The Role of CD-19 Targeting Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin Lymphoma
High Yield Medical ReviewsChimeric Antigen Receptor (CAR) T-cell therapy has improved outcomes in multiple hematological malignancies, such as multiple myeloma and non-Hodgkin lymphoma.
Emaan Haque +4 more
doaj +1 more source
RADIATION FREE THERAPY OR THE INITIAL TREATMENT OF GOOD PROGNOSIS EARLY NON‐BULKY HODGKIN LYMPHOMA, DEFINED BY A LOW METABOLIC TUMOR VOLUME AND A NEGATIVE PET‐2 ‐ RAFTING TRIAL [PDF]
, 2021 Andrea Gallamini +13 more
openalex +1 more source
TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy
Advanced Science, EarlyView.We developed TriCON, a triple‐modality nanotherapeutic platform, to treat pancreatic ductal adenocarcinoma (PDAC) by synergizing gene editing, chemotherapy, and immunotherapy. TriCON utilizes CRISPR/Cas9 to target the poliovirus receptor (PVR), combined with nano‐encapsulated doxorubicin and checkpoint blockade. This approach achieved significant tumor
Xinyu Peng +9 more
wiley +1 more source
Primary non-hodgkin′s lymphoma of bone: Experience of a decade
Indian Journal of Pathology and Microbiology, 2010 Objective: To study the prevalence and characterization of primary non Hodgkin′s lymphoma of bone in a major referral center of Pakistan. Methodology: All cases of primary non Hodgkin′s lymphoma of bone, diagnosed at a referral center in ...
Qureshi Asim +3 more
doaj
Revista Brasileira de Hematologia e Hemoterapia, 2011 OBJECTIVE: To evaluate the use of high-dose sequential chemotherapy in a Brazilian population. METHODS: High-dose cyclophosphamide followed by autologous hematopoietic stem cell transplantation is an effective and feasible therapy for refractory/relapsed
Bruno Kosa Lino Duarte +12 more
doaj +1 more source